2011
DOI: 10.1016/j.ejcts.2011.01.076
|View full text |Cite
|
Sign up to set email alerts
|

Effective silencing of adhesion molecules on venous endothelial cells for protection of venous bypass grafts

Abstract: For the first time, a functional protection of HUEC in a model simulating physiologic vascular conditions by using nonviral transfection of the cells in a setup with high relevance for clinical applicability was demonstrated. Therefore, siRNA transfection of bypass material may develop into a new therapeutic option to improve the quality of venous graft material in the future.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
8
0

Year Published

2012
2012
2022
2022

Publication Types

Select...
7

Relationship

2
5

Authors

Journals

citations
Cited by 7 publications
(8 citation statements)
references
References 22 publications
0
8
0
Order By: Relevance
“…To measure velocities, images from these video sequences were digitalized at 25 frames/s, and the distance of movement of the MSC during the 10 s. interval was computed into pixels. All measurements were performed using customized software for image recognition as described previously (CellTracker, C. Zanke, University Hospital Tübingen, Germany) [34] .…”
Section: Methodsmentioning
confidence: 99%
“…To measure velocities, images from these video sequences were digitalized at 25 frames/s, and the distance of movement of the MSC during the 10 s. interval was computed into pixels. All measurements were performed using customized software for image recognition as described previously (CellTracker, C. Zanke, University Hospital Tübingen, Germany) [34] .…”
Section: Methodsmentioning
confidence: 99%
“…Both siRNA were designed using the siRNA Target Finder software and synthesized by Qiagen (Hilden, Germany). Two independent siRNAs were used to obtain a selective reduction of E-Selectin expression: siRNA#1 [32] was synthesized by Qiagen and siRNA#2 [33] was purchased by Santa Cruz Biotechnology Inc. (sc-29296, Santa Cruz, CA). Control, non-silencing fluorescently labeled siRNA was obtained from Qiagen (AllStars Negative Control siRNA, Hilden, Germany).…”
Section: Methodsmentioning
confidence: 99%
“…The employed experimental strategies include the use of 1) pharmacological agents, such as lidocaine, which was studied in vitro using standard tissue bath techniques45; 2) gene targeting, e.g. short interfering RNA (siRNA)-mediated silencing of adhesion molecule46; and two additional methods that are elaborated hereunder: 3) vein harvesting, and 4) external stents.…”
Section: Methods To Extend Saphenous Vein Graft Patencymentioning
confidence: 99%